U.S. Markets closed

aTyr Pharma, Inc. (LIFE)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
3.9700+0.0700 (+1.79%)
At close: 4:00PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close3.9000
Open3.9100
Bid3.8200 x 900
Ask4.1800 x 800
Day's Range3.8600 - 4.0500
52 Week Range2.1300 - 7.6200
Volume59,022
Avg. Volume102,368
Market Cap37.16M
Beta (5Y Monthly)2.33
PE Ratio (TTM)N/A
EPS (TTM)-3.5200
Earnings DateMay 12, 2020
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est11.50
  • Thomson Reuters StreetEvents

    Edited Transcript of LIFE earnings conference call or presentation 12-May-20 9:00pm GMT

    Q1 2020 aTyr Pharma Inc Earnings Call

  • GlobeNewswire

    aTyr Pharma Presents Preclinical Research Showing NRP2 Antibody Effects in Triple-Negative Breast Cancer at the 2020 AACR Virtual Annual Meeting II

    SAN DIEGO, June 22, 2020 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel immunological pathways, today announced a poster and audio presentation at the 2020 American Association for Cancer Research (AACR) Virtual Annual Meeting II, which is being held June 22 – 24, 2020. The poster is available for browsing on the AACR website from June 22 – 24, 2020. The poster presents findings from a preclinical study, conducted in collaboration with Dr. Arthur M. Mercurio and his lab at the University of Massachusetts Medical School, demonstrating that aTyr has generated a panel of anti-human NRP2 monoclonal antibodies that have the potential to be developed for the clinical management of solid tumors.

  • GlobeNewswire

    aTyr Pharma Highlights New Literature Implicating Neuropilin Pathway In SARS-CoV-2 Infection

    Discovery that Neuropilin b1 domain acts as a binding site for SARS-CoV-2 Spike protein and aids viral entry. Lead therapeutic candidate, ATYR1923, modulates Neuropilin pathway to dampen inflammatory responses. SAN DIEGO, June 17, 2020 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel immunological pathways, today highlighted new external research demonstrating the involvement of Neuropilin biology in SARS-CoV-2 infection.